3 active not recruiting. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 3 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Advanced Solid Cancer: new trials by email Literature Review of Advanced Solid Cancer trials Research Report on Advanced Solid Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation ARV-806 - KRAS G12D Mutation, Advanced Solid Cancer | Phase 1 / Phase 2 | Active not recruiting | Arvinas Inc. | 76 | 2025-05-29 | 2026-09-16 |
| A Study of SHR-A1904 in Patients With Advanced Solid Cancer SHR-A1904 - Advanced Solid Cancer | Phase 1 | Active not recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 107 | 2021-07-01 | 2025-03-25 |
| A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor BPI-16350 - Advanced Solid Cancer | Phase 1 | Active not recruiting | Betta Pharmaceuticals Co., Ltd. | 54 | 2019-07-18 | 2025-01-27 |
Adenocarcinoma Of Esophagus (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Gallbladder Neoplasms (1) · Melanoma (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1) · Thyroid Neoplasms (1)
Adenocarcinoma (1) · Adnexal Diseases (1) · Biliary Tract Diseases (1) · Biliary Tract Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gallbladder Diseases (1)
Arvinas Inc. (1) · Betta Pharmaceuticals Co., Ltd. (1) · Shanghai Hengrui Pharmaceutical Co., Ltd. (1)
China (2) · United States (1)
2025 (1)